RELMADA THERAPEUTICS, INC. - Form 8-K Summary
Business Context and Reporting Period
RELMADA THERAPEUTICS, INC. (RLMD) filed this Current Report on Form 8-K on March 23, 2022. The filing announces a corporate update and reports preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2021. The Company is incorporated in Nevada and trades on The NASDAQ Stock Market LLC.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It serves as a notification that these results were issued in a press release (Exhibit 99.1) and will be fully detailed in the upcoming Annual Report on Form 10-K.
Material Changes
No specific material changes or comparative financial data versus the prior period are disclosed within the body of this 8-K filing. The document references the attached press release for the details of the fourth quarter and full-year 2021 performance.
Guidance, Outlook, and Risks
Management announced a conference call and audio webcast on March 23, 2022, at 4:30 PM EDT to discuss the corporate update and financial results. The filing includes standard legal disclaimers stating that the information furnished in Item 2.02 and Exhibit 99.1 is not deemed "filed" under the Exchange Act and shall not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review the attached Press Release (Exhibit 99.1) for specific Q4 and full-year 2021 financial figures.
- Verify the complete audited financial statements in the subsequent Form 10-K filing.
- Confirm the details of the corporate update discussed during the March 23, 2022, conference call.
- Monitor for any updates regarding the Company's cash position and burn rate, as specific liquidity numbers are not in this text.